SNS01-T for Patients with Relapsed Refractory Multiple Myeloma

UARK 2011-07, Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed Refractory Multiple Myeloma

 

Title: 

UARK 2011-07, Phase 1/2 Open-Label, Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of SNS01-T Administered by Intravenous Infusion in Patients with Relapsed Refractory Multiple Myeloma

Sponsor: 

Senesco

PI: 

Saad Usmani, MD

Phase: 

I/II

Purpose: 

SNS01-T has never been given to people and the main purpose of this Phase 1/2 study is to determine whether SNS01-T is safe for use when it is infused into your bloodstream twice per week for 6 weeks. 

Eligibility:  

Approximately 12 patients, male or female, age 18 or older, regardless of race or ethnicity, will participate in this study which is conducted at UAMS only. You are being asked to take part in this study because you have multiple myeloma which has returned or has not responded to two or more prior therapies.  Additionally, your physician feels that it may be reasonable for you to participate in this study of a possible new treatment for multiple myeloma. 

Treatment: 

Patients in this study will receive 1 of 4 dose levels of SNS01-T to see how the side effects from SNS01-T change at different doses.  The dose level you will receive is based on the order in which you enroll in the study (the earlier you enroll, the lower your dose) and how previous participants have reacted to their dose.  This study is also being done to learn how your body processes SNS01-T. 

Contact: 

Nathan Petty
E-mail: pettynathanm@uams.edu
Phone: 501-526-6990 ext. 2435